Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Youwei Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0144-5493; OpenAlex author ID A5061348827. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers

Papers 11

  1. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  2. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13402-023-00907-5↗
  3. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  4. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. First author DOI 10.1038/s41467-023-40314-w↗
  5. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Co-author DOI 10.1186/s12967-023-04702-6↗
  6. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  7. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Co-author DOI 10.1002/ctm2.654↗
  8. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. First author DOI 10.18632/aging.202264↗
  9. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  10. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Co-author DOI 10.1002/jcb.28457↗
  11. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes. Co-author DOI 10.1016/j.canlet.2017.09.044↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hao Chen · 8 shared papers, 2018–2023 · strength 0.97
  2. Baiyong Shen · 7 shared papers, 2018–2024 · strength 0.93
  3. Lingxi Jiang · 6 shared papers, 2021–2024 · strength 0.88
  4. Meilin Xue · 6 shared papers, 2021–2024 · strength 0.88
  5. Cheng Xiong · 5 shared papers, 2021–2023 · strength 0.73
  6. Chenghong Peng · 6 shared papers, 2018–2024 · strength 0.66
  7. Yizhi Cao · 4 shared papers, 2022–2024 · strength 0.61
  8. Lijie Han · 4 shared papers, 2022–2024 · strength 0.58
  9. Yihao Liu · 3 shared papers, 2022–2024 · strength 0.47
  10. Yongsheng Jiang · 3 shared papers, 2021–2023 · strength 0.43
  11. Xiaxing Deng · 3 shared papers, 2020–2024 · strength 0.42
  12. Xiaomei Tang · 2 shared papers, 2024 · strength 0.34
  13. Shuyu Zhai · 2 shared papers, 2024 · strength 0.34
  14. Weishen Wang · 2 shared papers, 2024 · strength 0.34
  15. Yang Liu · 2 shared papers, 2024 · strength 0.34
  16. Pengyi Liu · 2 shared papers, 2024 · strength 0.34
  17. Dongfeng Cheng · 3 shared papers, 2019–2024 · strength 0.33
  18. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.29
  19. Hao Chen · 2 shared papers, 2023–2024 · strength 0.29
  20. Xiaxing Deng · 2 shared papers, 2022–2024 · strength 0.28
  21. Gang Wei · 3 shared papers, 2018–2022 · strength 0.28
  22. Di Wang · 3 shared papers, 2018–2020 · strength 0.24
  23. Jiangning Gu · 3 shared papers, 2018–2020 · strength 0.24
  24. Shulin Zhao · 2 shared papers, 2019–2023 · strength 0.21
  25. Jiayu Lin · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.